BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40

Benzinga · 3d ago
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $39 to $40.